Scancell Holdings Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B63D3314
GBP
0.10
-0.01 (-5.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company declared negative results in Oct'24 after flat results in Apr'24

  • OPERATING CASH FLOW(Y) Lowest at GBP -24.8 MM
  • INTEREST(HY) At GBP 0.79 MM has Grown at 60.85%
  • OPERATING PROFIT(Q) Lowest at GBP -10.07 MM
2

Risky -

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 101 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.20

stock-summary
Return on Equity

367.35%

stock-summary
Price to Book

-26.38

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.75%
0%
17.75%
6 Months
-14.96%
0%
-14.96%
1 Year
3.11%
0%
3.11%
2 Years
-31.24%
0%
-31.24%
3 Years
-21.96%
0%
-21.96%
4 Years
-55.76%
0%
-55.76%
5 Years
73.95%
0%
73.95%

Scancell Holdings Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
41.69%
EBIT Growth (5y)
-173.35%
EBIT to Interest (avg)
-8.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.43
Tax Ratio
35.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-26.36
EV to EBIT
-6.69
EV to EBITDA
-7.11
EV to Capital Employed
-21.88
EV to Sales
21.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Scancell Holdings Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2023 is 0.00% vs 0.00% in Apr 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2023 is -158.70% vs 70.32% in Apr 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'23",
        "Apr'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.00",
          "val2": "-13.50",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.80",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-6.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-4.60",
          "chgp": "-158.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,261.40%",
          "val2": "0.00%",
          "chgp": "-226.14%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Apr'23stock-summary
Apr'23
Apr'22
Change(%)
Net Sales
5.30
0.00
Operating Profit (PBDIT) excl Other Income
-11.00
-13.50
18.52%
Interest
1.20
1.80
-33.33%
Exceptional Items
0.00
-6.30
100.00%
Consolidate Net Profit
-11.90
-4.60
-158.70%
Operating Profit Margin (Excl OI)
-2,261.40%
0.00%
-226.14%
USD in Million.
Net Sales

YoY Growth in year ended Apr 2023 is 0.00% vs 0.00% in Apr 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2023 is -158.70% vs 70.32% in Apr 2022

stock-summaryCompany CV
About Scancell Holdings Plc stock-summary
stock-summary
Scancell Holdings Plc
Pharmaceuticals & Biotechnology
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Company Coordinates stock-summary
Company Details
Department of Clinical Oncology, Hucknall Road OXFORD None : OX4 4GP
stock-summary
Tel: 44 115 8231863
stock-summary
Registrar Details